key: cord-0692711-yj9mb88g authors: Li, Dongbo; Ji, Hongfei; Niu, Xingjian; Yin, Lei; Wang, Yiran; Gu, Yucui; Wang, Jinlu; Zhou, Xiaoping; Zhang, Han; Zhang, Qingyuan title: Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer date: 2019-12-19 journal: Cancer Sci DOI: 10.1111/cas.14230 sha: 17f00e096a5f3ce94278a77011e6f38d7a47c618 doc_id: 692711 cord_uid: yj9mb88g Breast cancer is the most prevalent malignancy among women. Although endocrine therapy is effective, the development of endocrine resistance is a major clinical challenge. The tumor microenvironment (TME) promotes tumor malignancy, and tumor‐associated macrophages (TAM) within the TME play a crucial role in endocrine resistance. Herein, we aimed to elucidate the relationship between TAM and the endocrine‐resistant phenotype of breast cancer. Macrophages were cultured with conditioned medium (CM) from tamoxifen‐sensitive (MCF7‐S) or ‐resistant (MCF7‐R) MCF7 breast cancer cells. M2 polarization was detected by CD163 immunofluorescence. To determine the effect on endocrine resistance, MCF7 cells were cultured in the supernatant of different TAM, and then treated with tamoxifen. CC‐chemokine ligand 2 (CCL2) immunohistochemistry was carried out on pathological sections from 100 patients with invasive estrogen receptor‐positive breast cancer. We found that macrophages cultured in the CM of MCF7‐S and MCF7‐R cells were induced into TAM, with a more obvious M2 polarization in the latter. Tamoxifen resistance was increased by culture in TAM medium. TAM secreted CCL2, which increased endocrine resistance in breast cancer cells through activation of the PI3K/Akt/mTOR signaling pathway. High expression of CCL2 was correlated with infiltration of CD163+macrophages (r = 0.548, P < .001), and patients with high CCL2 expression presented shorter progression‐free survival than those with low CCL2 expression (P < .05). We conclude that CCL2 secreted by TAM activates PI3K/Akt/mTOR signaling and promotes an endocrine resistance feedback loop in the TME, suggesting that CCL2 and TAM may be novel therapeutic targets for patients with endocrine‐resistant breast cancer. Breast cancer is the most common cause of cancer-related mortality in women. 1 Approximately 70% of breast cancers are hormone receptor-positive. 2 Although endocrine therapy remains the most effective treatment, its efficacy is limited by intrinsic or acquired endocrine resistance. [3] [4] [5] Tamoxifen, a selective ER modulator, is the most common endocrine therapy worldwide 6 ; hence, resistance to tamoxifen is a major clinical challenge. Solid tumors such as breast cancer usually contain heterogeneous populations of neoplastic cells, immune cells, and collections of tissue-specific resident and recruited stromal cell types, which together form the TME. 7, 8 The relevance of this tumor heterogeneity is linked to various hallmarks of cancer including drug resistance. [9] [10] [11] [12] [13] [14] Macrophages are diverse cells that show distinct phenotypes depending on their anatomical location and activating stimuli. 15, 16 In breast cancer, macrophages can comprise up to 50% of the TME. 17 Among them, M2-type macrophages, commonly referred to as TAM, are associated with tumor malignancy. 18, 19 CD163, a scavenger receptor, is regarded as a highly specific monocyte/macrophage marker for M2 polarization. 20 Escamilla et al reported that TAM are involved in the resistance of patients with prostate cancer to androgen blockade therapy. 21 In our previous study, we found a correlation between TAM and tamoxifen resistance in patients with breast cancer, but the underlying mechanism has not been elucidated. 22 Tumor-associated macrophages secrete a variety of chemokines into the TME including CCL2, which is secreted mainly by macrophages when cocultured with MCF7 cells. 23 CCL2 is also known as MCP-1 and small inducible cytokine A2. CCL2 belongs to the CC chemokine family that recruits monocytes, memory T cells, and dendritic cells to sites of inflammation. 24, 25 Several studies have reported that CCL2 and the inflammatory environment promote the malignant behavior of different tumors. [26] [27] [28] Xu et al found that CCL2 recruits monocytes to the TME and polarizes macrophages into the M2 type. 25 Secretion of CCL2 is also an important manifestation of TAM polarization in macrophages. 29 Ueno et al showed that a high level of CCL2 expression is a significant indicator of earlier relapse. 30 However, there have been only a few studies on the role of CCL2 in endocrine resistance of breast cancer. The molecular mechanism underlying endocrine resistance of breast cancer is highly complicated and involves many molecules and pathways such as overexpression of epidermal growth factor receptor and/or the HER-2/neu/ErbB2 oncogene, 31 mutations in ER or loss of ER-alpha expression, 32,33 activation of the MAPK 32 and PI3K/Akt/mTOR signaling pathways, 34 and overexpression of cytochrome P450 (CYP450) enzymes. 35 Among these factors, the activation of the PI3K/Akt/mTOR signaling pathway is dominant. Thota et al observed induction of endocrine resistance by tumor macrophages, although the intrinsic molecular mechanism remains unclear. 36 The aim of the present study was to explore the interaction between TAM and the endocrine-resistant phenotype in breast cancer. CM from tamoxifen-sensitive and -resistant breast cancer cells was tested for its ability to induce macrophage M2 polarization. We then examined the role of TAM in promoting tamoxifen resistance. We also identified a specific cytokine, CCL2, secreted by TAM to promote endocrine resistance and investigated its underlying mechanism of action. CCL2 immunohistochemistry was carried out on pathological sections from patients with invasive ER-positive breast cancer to examine the correlation between CCL2 expression and disease prognosis. Our findings will further the understanding of how TAM promote tamoxifen resistance in breast cancer cells and may identify novel therapeutic targets for patients with endocrine-resistant breast cancer. Cell proliferation was assessed using CCK-8 (Vazyme) assay according to the manufacturer's instructions. Briefly, the cells were seeded in 96-well plates at a density of 1 × 10 4 cells/well and incubated with 5 μmol/L tamoxifen for 0, 12, 24, 36, 48, 60, and 72 hours. At the K E Y W O R D S breast cancer, CCL2, tamoxifen resistance, tumor microenvironment, tumor-associated macrophage end of the respective incubation times, the cells were incubated in complete medium containing 10% CCK-8 reagent for 2 hours. Subsequently, absorbance of the sample was measured at 450 nm in a microplate reader (Tecan). The experiments were repeated three times. MΦ, MS, and MR human macrophages grown in small culture dishes were fixed with 4% paraformaldehyde for 30 minutes, followed by washing with PBS thrice. Cells were blocked with 5% BSA for 30 minutes, and then incubated with the anti-CD163 antibody (diluted 1:1000) at 4°C overnight. Signal was detected using Alexa Total RNA was extracted from MΦ, MS, and MR macrophages using Table S1 . CCL2 and tumor necrosis factor (TNF)α present in culture supernatants from MCF7-S, MCF7-R, MΦ, MS, and MR macrophages were quantified using specific ELISA kits (Quantikine Human CCL2 Immunoassay and Quantikine Human TNFα Immunoassay; R&D Systems) following the manufacturer's instructions. Concentration of the samples was estimated from the standard curve. CCL2 and TNFα levels below the detection limit of the assay were recorded as zero. Cells were lysed in RIPA buffer. Protein samples were sonicated followed by centrifugation at 17 153 g for 15 minutes. Supernatants were collected and protein concentrations were determined using the Bradford Assay (Bio-Rad). Protein lysates were then subjected to 4%-20% Tris-glycine SDS PAGE, and then transferred onto PVDF membranes according to the manufacturer's instructions (Invitrogen). The membranes were blocked in 5% milk-Tris-buffered saline with 0.1% Tween (TBS-T) at 23°C for 1 hour, followed by incubation with primary antibodies at 4°C overnight. On the following day, the membranes were washed with TBS-T thrice before incubation with HRP-conjugated secondary antibodies (Cell Signaling) at 23°C for 1 hour. Protein expression was visualized by ECL chemiluminescence (Promega) and quantified using Image J software (National Cancer Institute). Microporous membrane (8-μm pore size) Transwell inserts (Costar) were used in the chemotaxis assay. Briefly, 2 × 10 5 cells in 200 μL RPMI-1640 were added to the upper chamber, and 500 μL CM from MΦ, MS, MR, and MR + Bindarit was added to the lower chamber. THP-1 cells were allowed to migrate at 37°C for 1 hour in an atmosphere of 5% CO 2 /95% air, and then the inserts were fixed and stained with 0.1% crystal staining solution. Non-migratory cells were removed before the membrane was mounted and migratory cells were observed and counted under a microscope. The protocol for this study was approved by the Ethics Committee of positivity. CCL2 immunoreactivity was scored by staining intensity (negative, weak, moderate, or strong staining) and the percentage of positive tumor cells per core (≤25%, >25%-50%, >50%-75%, and >75%). Tissues were considered positive for CCL2 expression with ≥moderate staining intensity in >25% of the cells examined. Yellow granules indicated CD163 positivity. CD163 immunoreactivity was scored as the infiltration density of CD163+ macrophages ranging from 0 (absent) to 3 (dense). A score equal to or greater than 1 was regarded as positive. Data are expressed as mean ± SD. Statistical analyses were carried out using GraphPad Prism software (version 6.0) and SPSS Statistics software (Version 19.0). Multiple comparisons were evaluated using the one-way ANOVA. Correlation between CD163 and CCL2 was determined using Spearman rank-order correlation. Survival curves were analyzed using Kaplan-Meier method and curves were compared using the log-rank test. Multivariate survival analysis using the Cox regression proportional hazards model was carried out to adjust for clinical variables that may have statistical significance for prognosis in a univariate analysis. Results with P values <.05 were considered to be statistically significant (*P < .05, **P < .01). To examine the differences in the macrophages, cellular CD163 immunofluorescence and flow cytometry analysis were carried out on the MΦ, MS, and MR. CD163 is considered a polarization maker for TAM and M2. We found that CM from breast cancer cell lines increased CD163 expression in MΦ, indicating M2 polarization. CD163 expression was higher and M2 polarization was more significant in MR than in MS ( Figure 1B,C) . These observations indicate that macrophages can be polarized to assume different phenotypes in different microenvironments. Figure 2B ). Thus, we conclude that CCL2 is associated with endocrine resistance promoted by TAM. Two hormone receptor-positive cell lines, MCF7 and T47D, were selected to test the effect of CCL2. We confirmed that CCR2, the receptor of CCL2, was expressed in both cell lines ( Figure S1 ). CCL2 (100 nm/mL) was added to the two cell lines and the cells were cultured for 24 hours. Subsequently, tamoxifen (5 μmol/L) was added to all four groups (MCF7, MCF7+CCL2, T47D, and T47D+CCL2) and the cells were cultured for 24 hours. Cell viability was assessed using the CCK-8 assay ( Figure 2C,D) . The four groups were also analyzed by flow cytometry to detect apoptosis ( Figure 2E ,F). We found that CCL2 promotes endocrine resistance and reduces apoptotic proportion in the two hormone receptor-positive cell lines. We have shown that CCL2 is associated with endocrine resistance in MCF7 and T47D cell lines. As the PI3K/Akt/mTOR signaling pathway is a classic pathway regulating cell proliferation, apoptosis, and endocrine resistance, we investigated the effect of CCL2 on the activation of this pathway. When MCF7 cells were treated with 100 nmol/L CCL2, phosphorylation of Akt and mTOR was significantly increased. Adding CM of MR to MCF7 cells also activated the PI3K/Akt/mTOR signaling pathway. When MR was treated with 300 nmol/L Bindarit (a CCL2 synthesis inhibitor), the ability of the CM (MR + Bindarit) to increase the levels of phosphorylated Akt and mTOR was weakened ( Figure 2G ). These results suggest that TAM promote endocrine resistance in breast cancer cells partly by secreting CCL2, which then activates the PI3K/Akt/ mTOR pathway. CCL2 secretion has been thought to be dependent on the transcription factor NF-κB, which is activated by TNFα in TME. 44 We tested whether breast cancer cells and macrophages pro- expression independent of NF-κB signaling by dephosphorylating the transcription factor FOXK1. 45 We tested the activation of the mTORC1-FOXK1 pathway in MΦ, MS, and MR and found that activation of the mTORC1-FOXK1 pathway was consistent with the secretion trend of CCL2 ( Figure 3C ). These results suggest that TNFα and amino acid metabolism in CM activate the NF-κB and mTORC1-FOXK1 pathways of TAM promoting the secretion of CCL2. As a well-known chemokine abundantly present in macrophages, CCL2 is responsible for the recruitment of monocytes. [37] [38] [39] [40] [41] [42] 46 The concentration of CCL2 is positively correlated with its chemotaxispromoting potential. We have already determined that the levels of CCL2 secreted by MΦ, MS, and MR are different. The next question is whether the chemotaxis of THP-1 cells induced by these three F I G U R E 2 CC-chemokine ligand 2 (CCL2) secreted by tumor-associated macrophages (TAM) activates the PI3K/Akt/mTOR pathway to induce endocrine resistance in breast cancer cells. A, RT-PCR shows the transcription of seven cytokines in three macrophages, MΦ, TAM from a tamoxifen-sensitive tumor microenvironment (TME) (MS), and TAM from tamoxifen-resistant TME (MR). Only the change trend of CCL2 is consistent with the previous experiment results, and the difference was statistically significant. B, CCL2 levels in the conditioned medium (CM) of tamoxifen-sensitive MCF7 breast cancer cells (MCF7-S), tamoxifen-resistant MCF7 breast cancer cells (MCF7-R), MΦ, MS, and MR cells. CCL2 was mainly produced by macrophages rather than breast cancer cells. C, Relative viability of MCF7 and MCF7 + CCL2 (100 nm/mL) cells treated with 5 μmol/L tamoxifen. D, Relative viability of T47D and T47D + CCL2 (100 nm/mL) cells treated with 5 μmol/L tamoxifen. E, Apoptosis of MCF7 and MCF7 + CCL2 (100 nm/mL) cells was analyzed by flow cytometry at 24 h after adding 5 μmol/L tamoxifen. F, Apoptosis of T47D and T47D + CCL2 (100 nm/mL) cells was analyzed by flow cytometry at 24 h after adding 5 μmol/L tamoxifen. G, Western blot analysis of the PI3K/Akt/mTOR pathway. CCL2 and CM of MR could activate the PI3K/AKT/mTOR pathway in MCF7 cells. When MR was treated with Bindarit for 24 h, activation of the PI3K/AKT/mTOR pathway by CM decreased. *P < .05, **P < .01, ***P < .001 F I G U R E 3 Tamoxifen-sensitive MCF7 breast cancer cells (MCF7-S) and tamoxifen-resistant MCF7 breast cancer cells (MCF7-R) secrete tumor necrosis factor (TNF)α and induce activation of the nuclear factor kappa B (NF-κB) and mTORC1-FOXK1 pathways in tumor-associated macrophages (TAM). A, TNFα levels in conditioned medium (CM) from MCF7-S, MCF7-R, MΦ, TAM from a tamoxifen-sensitive tumor microenvironment (TME) (MS), and TAM from tamoxifen-resistant TME (MR) cells. Level of TNFα in the CM of TAM was higher, but the difference between MS and MR was not significant (NS). B, Western blot analysis of the NF-κB pathway. CM of MCF7-S and MCF7-R could activate the NF-κB pathway of TAM. C, Western blot analysis of the mTORC1-FOXK1 pathway. CM of MCF7-S and MCF7-R could activate the mTORC1-FOXK1 pathway of TAM. Dephosphorylation of MR was more obvious than that of MS. Therefore, CM of MCF7-R can promote activation of the mTORC1-FOXK1 pathway more than MCF7-S. *P < .05, **P < .01 macrophages coincides with the secretion of CCL2. Results of the chemotaxis assay confirmed that the chemotaxis-inducing effect of TAM toward THP-1 cells was stronger than that of macrophages, the chemotaxis-inducing effect of MR was stronger than that of MS, and Bindarit the inhibitor of CCL2 reverses the enhanced chemotaxis ability of MR ( Figure 4A ). To further validate this phenomenon in vitro, we analyzed tissue samples from 100 patients with ER-positive breast cancer. Immunohistochemistry of serial pathological sections showed that a high expression of CCL2 in the paraneoplastic stroma was correlated with infiltration of CD163+ macrophages (r = 0.548, P < .001) ( Figure 4B and Table S2 ). We propose that tumor cells stimulate M2 polarization of macrophages, which leads to increased secretion of CCL2, and a high concentration of CCL2 in turn promotes THP-1 aggregation to form more M2-like macrophages. To determine the clinical relevance of CCL2 and endocrine resistance in the in vitro findings, we selected 100 patients with invasive ER-positive breast cancer who received regular endocrine therapy at the Tumor Hospital of Harbin Medical University from 2004 to 2014 F I G U R E 4 High concentration of CC-chemokine ligand 2 (CCL2) recruits monocytes and macrophages to facilitate an endocrine-resistant microenvironment in breast cancer. A, Representative photos of THP-1 cells recruited by the conditioned medium (CM) of MΦ, TAM from a tamoxifen-sensitive tumor microenvironment (TME) (MS), TAM from tamoxifen-resistant TME (MR), and MR + Bindarit after the chemotaxis assay. Quantitative results show that the chemotaxis ability of TAM to recruit THP-1 cells was enhanced, and TAM in the endocrine-resistant environment had stronger chemotaxis ability. Bindarit reverses the enhanced chemotaxis ability of CM (MR). B, Representative images of immunohistochemical staining for CCL2 and CD163 and HE staining in serial sections from human breast cancer samples. The related correlation analyses showed r = .548. *P < .05, **P < .01 F I G U R E 5 CC-chemokine ligand 2 (CCL2) expression in the stroma correlated with poor recurrence-free survival of patients with hormone receptor-positive breast cancer. A, Different patterns of CCL2 immunohistochemical staining in the stroma of breast cancer cells. B, Kaplan-Meier recurrence-free survival curves of patients with hormone receptorpositive breast cancer with low (n = 71) and high (n = 29) CCL2 expression in the stroma (P = .029). C, Proposed model for TAM-secreted CCL2 activating the PI3K/Akt/mTOR pathway to promote a malignant cycle of endocrine resistance and recruitment of monocytes (Table S3) Results showed that PFS of the CCL2 high-expression group was significantly shorter than that of the CCL2 low-expression group (P < .05). The prognostic value of each clinicopathological feature was assessed using Cox hazard regression analysis. CCL2 expression was found to be an independent risk factor for disease-free survival (DFS) (HR = 2.323, P = .015) ( Table 1) . Taken together, these results indicate a crucial role of CCL2 in promoting endocrine resistance in breast cancer. We also found that TAM promote endocrine resistance by secreting CCL2, which activates the PI3K/Akt/mTOR signaling pathway. Therefore, CCL2 plays an important role in this malignant feedback loop. In addition, CCL2 promotes the aggregation of monocytes and macrophages in the TME. 48 The transition from monocytes to TAM further promotes the formation of the endocrine-resistant microenvironment. Analysis of tissue samples from patients with hormone receptor-positive breast cancer confirmed a correlation between high expression of CCL2 in the paraneoplastic stroma and infiltration of CD163+ macrophages. Moreover, patients with high CCL2 expression in the stroma had a shorter PFS after endocrine therapy. This is consistent with the findings of our previous study that patients with high CD163+ macrophage infiltration tend to develop endocrine resistance. 22 The finding that CCL2 promotes the formation of the TME and the malignant cycle of cells in the TME may partly explain why patients with endocrine resistance in the past are more likely to be resistant to new endocrine therapy. Tumor-associated macrophages can adjust their phenotype and function in response to local cues provided by the TME. 49 Crosstalk between TAM and cancer cells is complex and involves exosomes, cytokines, and metabolites. [50] [51] [52] In the present study, we focused on the cytokine CCL2 secreted by macrophages and TA B L E 1 Univariate and multivariate analyses of clinicopathological features associated with PFS of patients with hormone receptor-positive breast cancer examined its role in the endocrine resistance of breast cancer cells. We found that CCL2 activates the PI3K/Akt/mTOR pathway, which is a classical endocrine resistance pathway. However, the direct mechanism by which CCL2 activates this pathway was not determined. Another limitation of the present study was that due to the long culture time of drug-resistant cell lines, the effects of endocrine-resistant and -sensitive T47D cell lines on macrophages could not be repeated. Cell components in the TME are complex. In addition to TAM, fibroblasts, dendritic cells, epithelial cells, neutrophils, and lymphocytes can also be tamed by tumor cells and promote a tumor malignant environment. [53] [54] [55] [56] [57] [58] It has been reported that dendritic cells, fibroblasts, and epithelial cells tamed by cancer cells secrete CCL2. 55 This study was financially supported by the National Natural Science Authors declare no conflicts of interest for this article. Cancer statistics Biological determinants of endocrine resistance in breast cancer Cellular and molecular pharmacology of antiestrogen action and resistance Endocrine-responsive breast cancer and strategies for combating resistance Endocrine resistance in breast cancer: current status and a perspective on the roles of miRNAs (review) Tamoxifen metabolism and its effect on endocrine treatment of breast cancer Accessories to the crime: functions of cells recruited to the tumor microenvironment The biology and function of fibroblasts in cancer Breast cancer stem cells as last soldiers eluding therapeutic burn: a hard nut to crack The cellular origin and evolution of breast cancer. Cold Spring Harb Perspect Med Regulatory T cells in cancer immunotherapy Organotypic vasculature: From descriptive heterogeneity to functional pathophysiology Limits to Precision Cancer Medicine EMT, CSCs, and drug resistance: the mechanistic link and clinical implications New insights into the multidimensional concept of macrophage ontogeny, activation and function Macrophage activation and polarization: nomenclature and experimental guidelines The role of tumor-associated macrophages in breast cancer progression (review) Diverse macrophages polarization in tumor microenvironment Distinct role of macrophages in different tumor microenvironments CD163: A specific marker of macrophages in paraffin-embedded tissue samples CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9 Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes Linking tumor-associated macrophages, inflammation, and intestinal tumorigenesis: role of MCP-1 Pathologic evaluation of tumor-associated macrophage density and vessel inflammation in invasive breast carcinomas A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer Estrogen receptor mutations in human disease Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen Mechanisms of resistance to structurally diverse antiestrogens differ under premenopausal and postmenopausal conditions: evidence from in vitro breast cancer cell models Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor Detection of cytochrome P450 polymorphisms in breast cancer patients may impact on tamoxifen therapy The inflammatory chemokines CCL2 and CCL5 in breast cancer Guanylate binding protein 1 inhibits osteogenic differentiation of human mesenchymal stromal cells derived from bone marrow SARS coronavirus papain-like protease induces Egr-1-dependent up-regulation of TGF-β1 via ROS/p38 Expression profiles of the immune genes CD4, CD8β, IFNγ, IL-4, IL-6 and IL-10 in mitogen-stimulated koala lymphocytes (Phascolarctos cinereus) by qRT-PCR The differentially expressed genes by radiotherapy in the patients with uterine cervix cancer (Korean) Cloning and expression of chicken granulocyte-macrophage colony stimulating factor (GMCSF) gene Tumor-associated immune factors are associated with recurrence and metastasis in nonsmall cell lung cancer Tumor-associated stromal cells as key contributors to the tumor microenvironment Noncanonical pathway for regulation of CCL2 expression by an mTORC1-FOXK1 axis promotes recruitment of tumor-associated macrophages Th17 cells regulate the production of CXCL1 in breast cancer Macrophages promote circulating tumor cell-mediated local recurrence following radiation therapy in immunosuppressed patients Monocyte chemoattractant protein-1 in acute coronary syndromes: complex vicious interaction Environment drives selection and function of enhancers controlling tissue-specific macrophage identities Identification and manipulation of tumor associated macrophages in human cancers Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells Th17 cells regulate the production of CXCL1 in breast cancer IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration 6-Shogaol, an active constituent of dietary ginger, impairs cancer development and lung metastasis by inhibiting the secretion of CC-chemokine ligand 2 (CCL2) in tumor-associated dendritic cells CCL2 is a potent regulator of prostate cancer cell migration and proliferation Perspective on the osteoclast: an angiogenic cell? Additional supporting information may be found online in the Supporting Information section.